Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata

AIDS

Volumn 25, Issue 18, 2011, Pages 2259-2268

  Reekie, Joanne ^a   Gatell, Jose M ^b   Yust, Israel ^c   Bakowska, Elzbieta ^d   Rakhmanova, Aza ^e   Losso, Marcelo ^f   Krasnov, Maksym ^g   Francioli, Patrick ^h   Kowalska, Justyna D ⁱ   Mocroft, Amanda ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b HOSPITAL CLÍNIC   (Spain)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^d SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

^e Medical Academy Botkin Hospital   (Russian Federation)

^f HOSPITAL RAMOS MEJÍA   (Argentina)

^g KHARKIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^h LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

ⁱ UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

AIDS; CD4 cell count; non AIDS events; viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; ESOPHAGUS CANDIDIASIS; EUROPE; FATALITY; FEMALE; FOLLOW UP; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; KAPOSI SARCOMA; KIDNEY DISEASE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PANCREATITIS; PRIORITY JOURNAL; RECURRENT DISEASE; SKIN ULCER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA; VIREMIA; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ARGENTINA; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; EUROPE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; ISRAEL; MALE; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD; VIREMIA;

EID: 80855132759     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834cdb4b     Document Type: Article

References (24)

1. Darbyshire J, Schoenfeld DA, Weller IV. Clinical trials in HIV infection: current problems and future directions. AIDS 1991; 5 (Suppl 2):S167-S173.
2. Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186:189-197. (Pubitemid 34765506)
3. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291-296. (Pubitemid 30459587)
4. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143-2153.
5. Ferry T, Raffi F, Collin-Filleul F, Dupon M, Dellamonica P, Waldner A, et al. Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study. J Acquir Immune Defic Syndr 2009; 51:407-415.
6. Mocroft A, Reiss P, Gasiorowski J, Ledergerber B, Kowalska J, Chiesi A, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262-270.
7. Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, et al. Inferior clinical outcome of the CD4R cell countguided antiretroviral treatment interruption strategy in the SMART study: role of CD4R cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197:1145-1155. (Pubitemid 351590050)
8. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4(R) T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000; 181: 946-953. (Pubitemid 30194478)
9. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730. (Pubitemid 28534954)
10. Kowalska JD, Friis-Moller N, Kirk O, Bannister W, Mocroft A, Sabin C, et al. The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology. Epidemiology 2011; 22:516-523.
11. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999; 13:943-950. (Pubitemid 29240189)
12. Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, et al. Cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA Study. HIV Clin Trials 2011; 12:109-117.
13. Loveday C, Hill A. Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet 1995; 345:790-791.
14. Sabin CA, Devereux H, Phillips AN, Janossy G, Loveday C, Lee CA. Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men. AIDS 1998; 12:1347-1352. (Pubitemid 28330728)
15. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4R lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-954. (Pubitemid 27255797)
16. Phillips A. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18:51-58. (Pubitemid 38402317)
17. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 2002; 16:1663-1671. (Pubitemid 34921112)
18. Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, et al. Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy. HIV Med 2008; 9:246-256. (Pubitemid 351467799)
19. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4R count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296. (Pubitemid 44837777)
20. Danel C,Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989. (Pubitemid 43867699)
21. Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, et al. Death rates in HIV-positive antiretroviralnaive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010; 376:340-345.
22. Marin B, Thiebaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 2009; 23:1743-1753.
23. Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10:1152-1159.
24. START protcol synopsis. http://insight.ccbr.umn.edu/official-documents/ START/protocol-documents/START-ProtocolSynopsis. pdf. [Accessed 19 November 2009]